Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Morphic Hold
Hot Stocks: 3 Sleeping Giants About to Dominate Their Sectors
02:24pm, Tuesday, 09'th Jul 2024
Some stocks fly under the radar of investors even as they quietly dominate the industry in which they operate. These stealth stocks rise to the top by developing competitive advantages.
3 Moonshot Stocks With the Potential to Turn $10K Into $1 Million
02:06pm, Tuesday, 09'th Jul 2024
With the Nasdaq and S&P 500 on a running spree, it is easy to pick stocks on momentum. But if you are investing for the long term, you need to pick stocks that will grow your money at little risk.
Novo Nordisk Falls as Study Says Eli Lilly Weight-Loss Ingredient More Effective
01:55pm, Tuesday, 09'th Jul 2024
The stock price of a pair of pharmaceutical companies are moving in opposite directions Tuesday following the publication of a new scientific study, with Eli Lilly (LLY) shares rising and American dep
Why Lilly (LLY) is Poised to Beat Earnings Estimates Again
01:11pm, Tuesday, 09'th Jul 2024
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's
01:05pm, Tuesday, 09'th Jul 2024
Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.
Eli Lilly weight-loss drug found more effective than Novo Nordisk's Ozempic
11:26am, Tuesday, 09'th Jul 2024
Novo Nordisk (NYSE:NVO) shares fell and Eli Lilly and Co (NYSE:LLY) rose after a study found the US company's weight-loss drug may be more effective. Lilly's tirzepatide, branded as Mounjaro, was
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
11:20am, Tuesday, 09'th Jul 2024
Eli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding the latter's lead candidate, MORF-057, which is being developed for IBD conditions.
Novo Nordisk's stock slumps after study finds Wegovy lags Lilly's Mounjaro in speed and scale of weight loss
07:34am, Tuesday, 09'th Jul 2024
The stock of Danish biotech Novo Nordisk was down 1.6% premarket Tuesday, after a study found that the company's obesity drug Wegovy lags its main rival, Eli Lilly & Co. Inc.'s Mounjaro, in speed and
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
07:18am, Tuesday, 09'th Jul 2024
Global pharmaceutical company Eli Lilly & Co. NYSE: LLY has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been going heads-up against GLP-1 leader Novo Nordisk
Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?
06:15am, Tuesday, 09'th Jul 2024
Lilly's recently approved Alzheimer's disease drug Kisunla could generate peak annual sales of close to $5 billion. However, the drugmaker has even more important growth drivers than Kisunla.
Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss
05:40am, Tuesday, 09'th Jul 2024
Shares in Novo Nordisk , maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to fa
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
05:15am, Tuesday, 09'th Jul 2024
Eli Lilly stock has soared on optimism about its top-selling weight-loss drugs. The company is expanding infrastructure to meet demand -- and is studying new potential weight-loss drugs in late-stage
Biggest indicators for weight loss drugs are yet to come, says Jim Cramer
08:14pm, Monday, 08'th Jul 2024
'Mad Money' host Jim Cramer talks today's massive tech run into a record close and how non-tech players are pushing toward the top.
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
07:44pm, Monday, 08'th Jul 2024
Patients lost more significantly more weight on Eli Lilly's Mounjaro than Novo Nordisk's Ozempic, according to a new study.
